Three-Year Outcomes Associated with Embolic Protection in Saphenous Vein Graft Intervention: Results in 49 325 Senior Patients in the Medicare-Linked National Cardiovascular Data Registry CathPCI Registry

Circulation: Cardiovascular Interventions

Volumn 8, Issue 3, 2015, Pages

  Brennan, J Matthew ^a   Al Hejily, Wesam ^a   Dai, David ^a   Shaw, Richard E ^b   Trilesskaya, Marina ^c   Rao, Sunil V ^a   Brilakis, Emmanouil S ^d   Anstrom, Kevin J ^a   Messenger, John C ^e   Peterson, Eric D ^a   Douglas, Pamela S ^a   Sketch, Michael H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Sutter Pacific Heart Centers   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

embolic protection devices

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD VESSEL DISSECTION; BLOOD VESSEL PERFORATION; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE SAFETY; EMBOLIC PROTECTION DEVICE; EMBOLISM; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICARE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; BLOOD VESSEL GRAFT; PROCEDURES; REGISTER; SAPHENOUS VEIN; STATISTICS AND NUMERICAL DATA; SURGERY; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EMBOLIC PROTECTION DEVICES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICARE; REGISTRIES; SAPHENOUS VEIN; TREATMENT OUTCOME; UNITED STATES; VASCULAR GRAFTING;

EID: 84937569301     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.001403     Document Type: Article

References (28)

1. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
2. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH; ACCF; AHA; SCAI. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2012;79:453-495. doi: 10.1002/ccd.23438.
3. Abdel-Karim AR, Papayannis AC, Mahmood A, Michael TT, Rangan BV, Makke L, Banerjee S, Brilakis ES. Role of embolic protection devices in ostial saphenous vein graft lesions. Catheter Cardiovasc Interv. 2012;80:1120-1126. doi: 10.1002/ccd.23471.
4. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A; Is Drug- Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators. Drug-eluting versus baremetal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011;378:1071-1078. doi: 10.1016/ S0140-6736(11)61255-5.
5. Senter SR, Nathan S, Gupta A, Klein LW. Clinical and economic outcomes of embolic complications and strategies for distal embolic protection during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol. 2006;18:49-53.
6. Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES, Vermeersch P, Kim YH, Waksman R, Mehilli J, Mauri L, Stone GW. Saphenous vein graft intervention. JACC Cardiovasc Interv. 2011;4:831-843. doi: 10.1016/j.jcin.2011.05.014.
7. Narayanan A, Abdallah M, Helmy T. Embolic protection devices in saphenous vein graft interventions: is there still a role? J Invasive Cardiol. 2012;24:4.
8. Satler LF. Do we still need distal protection in the treatment of SVG disease? Catheter Cardiovasc Interv. 2008;72:804-805. doi: 10.1002/ ccd.21864.
9. Mehta SK, Frutkin AD, Milford-Beland S, Klein LW, Shaw RE, Weintraub WS, Krone RJ, Anderson HV, Kutcher MA, Marso SP; American College of Cardiology-National Cardiovascular Data Registry. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19 546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol. 2007;100:1114-1118. doi: 10.1016/j.amjcard.2007.04.058.
10. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37:2240-2245.
11. Hammill BG, Hernandez AF, Peterson ED, Fonarow GC, Schulman KA, Curtis LH. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J. 2009;157:995-1000. doi: 10.1016/j. ahj.2009.04.002.
12. Brennan JM, Peterson ED, Messenger JC, Rumsfeld JS, Weintraub WS, Anstrom KJ, Eisenstein EL, Milford-Beland S, Grau-Sepulveda MV, Booth ME, Dokholyan RS, Douglas PS; Duke Clinical Research Institute DEcIDE Team. Linking the National Cardiovascular Data Registry CathPCI Registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization. Circ Cardiovasc Qual Outcomes. 2012;5:134-140. doi: 10.1161/ CIRCOUTCOMES.111.963280.
13. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141-1154.
14. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrica. 1983;70:41-55.
15. Parsons L; Ovation Research Group. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Presented at SAS Users Group International Conference 26; 2001. Long Beach, California; 2001.
16. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating shortterm drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275. doi: 10.1097/01. ede.0000193606.58671.c5.
17. Dixon SR, Mann JT, Lauer MA, Casale PN, Dippel EJ, Strumpf RK, Feldman RL, Shear W, Resar JR, Zimmer SD, O'Neill WW; TRAP Investigators. A randomized, controlled trial of saphenous vein graft intervention with a filter-based distal embolic protection device: TRAP trial. J Interv Cardiol. 2005;18:233-241. doi: 10.1111/j.1540-8183.2005.00039.x.
18. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA; FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aortocoronary bypass grafts. Circulation. 2003;108:548-553. doi: 10.1161/01. CIR.0000080894.51311.0A.
19. Dixon SR, O'Neill WW; on behalf of the SPIDER Investigators. Saphenous Vein Graft Protection in a Distal Embolic Protection Randomized Trial. Presented at TCT 2005. http://www. clinicaltrialresults.org/Slides/ SPIDER%20Trial.ppt. Updated October 18, 2005. Accessed January 6, 2014. 20.
20. Zoghbi GJ, Goyal M, Hage F, Meyers RP, Papapietro SE, Brott BC, Misra VK, Iskandrian AE, Hillegass WB. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. J Invasive Cardiol. 2009;21:34-39.
21. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14:299-302.
22. Okabe T, Lindsay J, Torguson R, Steinberg DH, Roy P, Slottow TL, Kaneshige K, Xue Z, Satler LF, Kent KM, Pichard AD, Waksman R. Can direct stenting in selected saphenous vein graft lesions be considered an alternative to percutaneous intervention with a distal protection device? Catheter Cardiovasc Interv. 2008;72:799-803. doi: 10.1002/ ccd.21678.
23. Naidu SS, Turco MA, Mauri L, Coolong A, Popma JJ, Kereiakes DJ. Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy). Am J Cardiol. 2010;105:1060-1064. doi: 10.1016/j.amjcard.2009.12.004.
24. Kirtane AJ, Heyman ER, Metzger C, Breall JA, Carrozza JP Jr. Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy. JACC Cardiovasc Interv. 2008;1:186-191. doi: 10.1016/j.jcin.2008.01.002.
25. Porto I, Cautilli G, Camaioni C. Immediate evidence of the benefit of distal protection in vein graft intervention. J Cardiovasc Med (Hagerstown). 2012;13:828-829. doi: 10.2459/JCM.0b013e328347c3aa.
26. Steigen SE, Steigen TK, Gunnes P, Thuesen L, Mannsverk J, Jørgensen L. Histopathology of material captured by embolic protection device after percutaneous coronary interventions in atherosclerotic saphenous vein grafts. EuroIntervention. 2006;2:244-249.
27. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G; DELAYED RRISC (Death and Events at Longterm follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261-267. doi: 10.1016/j.jacc.2007.05.010.
28. Lauer MS, D'Agostino RB Sr. The randomized registry trial-the next disruptive technology in clinical research? N Engl J Med. 2013;369: 1579-1581. doi: 10.1056/NEJMp1310102.